Andrew K. Choi: Debarment Order, 48168-48169 [2011-19976]
Download as PDF
48168
Federal Register / Vol. 76, No. 152 / Monday, August 8, 2011 / Notices
information, a listing of all drug or
device products manufactured,
prepared, propagated, compounded, or
processed by him or her for commercial
distribution. In part 607 (21 CFR part
607), FDA has issued regulations
implementing these requirements for
manufacturers of human blood and
blood products.
Section 607.20(a), in brief, requires
owners or operators of certain
establishments that engage in the
manufacture of blood products to
register and to submit a list of every
blood product in commercial
distribution. Section 607.21, in brief,
requires the owners or operators of
establishments entering into the
manufacturing of blood products to
register within 5 days after beginning
such operation and to submit a list of
every blood product in commercial
distribution at the time. If the owner or
operator of the establishment has not
previously entered into such operation
for which a license is required,
registration must follow within 5 days
after the submission of a biologics
license application. In addition, owners
or operators of all establishments so
engaged must register annually between
November 15 and December 31 and
must update their blood product listing
information every June and December.
Section 607.22 requires the use of Form
FDA 2830 (Blood Establishment
Registration and Product Listing) for
initial registration, subsequent annual
registration, and for blood product
listing information. Section 607.25 sets
forth the information required for
establishment registration and blood
product listing. Section 607.26, in brief,
requires certain changes to be submitted
on Form FDA 2830 as an amendment to
establishment registration within 5 days
of such changes. Section 607.30(a), in
brief, sets forth the information required
from owners or operators of
establishments when updating their
blood product listing information every
June and December, or at the discretion
of the registrant at the time the change
occurs. Section 607.31 requires that
additional blood product listing
information be provided upon FDA
request. Section 607.40, in brief,
requires certain foreign blood product
establishments to comply with the
establishment registration and blood
product listing information
requirements discussed above and to
provide the name and address of the
establishment and the name of the
individual responsible for submitting
establishment registration and blood
product listing information as well as
the name, address, and phone number
of its U.S. agent.
Among other uses, this information
assists FDA in its inspections of
facilities, and its collection is essential
to the overall regulatory scheme
designed to ensure the safety of the
nation’s blood supply. Form FDA 2830
is used to collect this information.
Respondents to this collection of
information are human blood and
plasma donor centers, blood banks,
certain transfusion services, other blood
product manufacturers, and
independent laboratories that engage in
quality control and testing for registered
blood product establishments.
FDA estimates the burden of this
collection of information based upon
information obtained from FDA’s Center
for Biologics Evaluation and Research’s
database and FDA experience with the
blood establishment registration and
product listing requirements.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
Number of
responses
per respondent
Total annual
responses
Average
burden per
response
(in hours)
21 CFR Section
Form FDA 2830
607.20(a), 607.21, 607.22, 607.25, and
607.40.
607.21, 607.22, 607.25, 607.26, 607.31, and
607.40.
607.21, 607.25, 607.30(a), 607.31, and
607.40.
Initial Registration .......
49
1
49
Re-registration ............
2,589
1
2,589
Product Listing Update
180
1
180
0.25
45
Total .........................................................
.....................................
....................
....................
....................
....................
1,388
1 There
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
mstockstill on DSK4VPTVN1PROD with NOTICES
Food and Drug Administration
[Docket No. FDA–2011–N–0126]
Andrew K. Choi: Debarment Order
Food and Drug Administration,
HHS.
Notice.
VerDate Mar<15>2010
18:57 Aug 05, 2011
Jkt 223001
The Food and Drug
Administration (FDA) is issuing an
order under the Federal Food, Drug, and
Cosmetic Act (the FD&C Act) debarring
Andrew K. Choi, M.D. for 4 years from
providing services in any capacity to a
person that has an approved or pending
drug product application. FDA bases
this order on findings that Dr. Choi was
convicted of a misdemeanor under
Federal law for conduct relating to the
regulation of a drug product under the
FD&C Act and that the type of conduct
underlying the conviction undermines
the process for the regulation of drugs.
Dr. Choi was given notice of the
proposed debarment and an opportunity
to request a hearing within the
timeframe prescribed by regulation. Dr.
Choi failed to respond. Dr. Choi’s failure
SUMMARY:
[FR Doc. 2011–19955 Filed 8–5–11; 8:45 am]
ACTION:
1
0.5
49
1,294
are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: July 26, 2011.
David Dorsey,
Acting Deputy Commissioner for Policy,
Planning and Budget.
AGENCY:
Total hours
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
to respond constitutes a waiver of his
right to a hearing concerning this action.
DATES:
This order is effective August 8,
2011.
Submit applications for
termination of debarment to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville,
MD 20852.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Kenny Shade, Division of Compliance
Policy (HFC–230), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–796–4640.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\08AUN1.SGM
08AUN1
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 76, No. 152 / Monday, August 8, 2011 / Notices
I. Background
Section 306(b)(2)(B)(i)(I) of the FD&C
Act (21 U.S.C. 335a(b)(2)(B)(i)(I))
permits FDA to debar an individual if it
finds that the individual has been
convicted of a misdemeanor under
Federal law for conduct relating to the
regulation of drug products under the
FD&C Act, and if FDA finds that the
type of conduct that served as the basis
for the conviction undermines the
process for the regulation of drugs.
On April 2, 2007, Dr. Choi pleaded
guilty to one count of receipt in
interstate commerce of a misbranded
drug and delivery thereof in violation of
sections 301(c), 303(c), and 502(f) of the
FD&C Act (21 U.S.C. 331(c), 333(a)(1),
and 352(f)). On August 11, 2008, the
U.S. District Court for the Central
District of California entered judgment
against Dr. Choi for the misdemeanor
offense of receipt in interstate commerce
of a misbranded drug and delivery
thereof.
FDA’s finding that debarment is
appropriate is based on the
misdemeanor conviction referenced
herein. The factual basis for the
conviction is as follows: Dr. Choi was a
licensed physician in the State of
California. Prior to November 13, 2003,
Dr. Choi injected patients with Botox®,
an FDA-approved Botulinum Toxin
Type A drug product manufactured by
Allergan, Inc. In 2003, Dr. Choi began
ordering an unapproved drug purported
to be Botulinum Toxin Type A (TRI–
Toxin) manufactured by Toxin Research
International, Inc. (TRI), located in
Tucson, Arizona, instead of the
approved Botox®. From on or about
November 13, 2003, and continuing
until about August 3, 2004, Dr. Choi
placed 14 orders for a total of 28 vials
of TRI–Toxin, which he had shipped to
his office in the Central District of
California. The TRI–Toxin did not come
with labeling or directions on how to
dilute the product for injection. The
TRI–Toxin label stated ‘‘for research
purposes only’’ and ‘‘not for human
use,’’ as did the TRI–Toxin invoices. Dr.
Choi admitted to injecting the TRI–
Toxin into his employees and patients.
Between on or about November 13,
2003, and continuing until on or about
August 3, 2004, Dr. Choi received and
delivered the TRI–Toxin when he
administered it to other persons, all in
violation of sections 301(c), 303(c), and
502(f) of the FD&C Act.
As a result of his conviction, on April
22, 2011, FDA sent Dr. Choi a notice by
certified mail proposing to debar him
for 4 years from providing services in
any capacity to a person that has an
approved or pending drug product
VerDate Mar<15>2010
18:57 Aug 05, 2011
Jkt 223001
application. FDA subsequently
confirmed on May 9, 2011, that Dr. Choi
personally received the notice. The
proposal was based on a finding, under
section 306(b)(2)(B)(i)(I) of the FD&C
Act that Dr. Choi was convicted of a
misdemeanor under Federal law for
conduct relating to the regulation of
drug products under the FD&C Act, and
that the conduct that served as a basis
for the conviction undermines the
process for the regulation of drugs. The
proposal also offered Dr. Choi an
opportunity to request a hearing,
providing him 30 days from the date of
receipt of the letter in which to file the
request, and advised him that failure to
request a hearing constituted a waiver of
the opportunity for a hearing and of any
contentions concerning this action. Dr.
Choi failed to respond within the
timeframe prescribed by regulation and
has therefore, waived his opportunity
for a hearing and waived any
contentions concerning his debarment
(21 CFR part 12).
II. Findings and Order
Therefore, the Director, Office of
Enforcement, Office of Regulatory
Affairs, under section 306(b)(2)(B)(i)(I)
of the FD&C Act under authority
delegated to him (Staff Manual Guide
1410.35), finds that Andrew K. Choi has
been convicted of a misdemeanor under
Federal law for conduct relating to the
regulation of a drug product under the
FD&C Act, and that the type of conduct
that served as a basis for the conviction
undermines the process for the
regulation of drugs.
As a result of the foregoing finding,
Dr. Choi is debarred for 4 years from
providing services in any capacity to a
person with an approved or pending
drug product application under sections
505, 512, or 802 of the FD&C Act (21
U.S.C. 355, 360b, or 382), or under
section 351 of the Public Health Service
Act (42 U.S.C. 262), effective (see
DATES), (see sections 306(c)(1)(B),
(c)(2)(A)(iii), and 201(dd) of the FD&C
Act (21 U.S.C. 335a(c)(1)(B),
(c)(2)(A)(iii), and 321(dd))). Any person
with an approved or pending drug
product application who knowingly
employs or retains as a consultant or
contractor, or otherwise uses the
services of Dr. Choi, in any capacity
during Dr. Choi’s debarment, will be
subject to civil money penalties (section
307(a)(6) of the FD&C Act (21 U.S.C.
335b(a)(6))). If Dr. Choi provides
services in any capacity to a person with
an approved or pending drug product
application during his period of
debarment he will be subject to civil
money penalties (section 307(a)(7) of the
FD&C Act). In addition, FDA will not
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
48169
accept or review any abbreviated new
drug applications submitted by or with
the assistance of Dr. Choi during his
period of debarment (section
306(c)(1)(B) of the FD&C Act).
Any application by Dr. Choi for
termination of debarment under section
306(d)(1) of the FD&C Act (21 U.S.C.
335a(d)(1)) should be identified with
Docket No. FDA–2011–N–0126 and sent
to the Division of Dockets Management
(see ADDRESSES). All such submissions
are to be filed in four copies. The public
availability of information in these
submissions is governed by 21 CFR
10.20(j).
Publicly available submissions may
be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
Dated: July 27, 2011.
Armando Zamora,
Acting Director, Office of Enforcement, Office
of Regulatory Affairs.
[FR Doc. 2011–19976 Filed 8–5–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0557]
Advancing Regulatory Science for
Highly Multiplexed Microbiology/
Medical Countermeasure Devices;
Public Meeting
AGENCY:
Food and Drug Administration,
HHS.
Notice of public meeting;
request for comments.
ACTION:
The Food and Drug Administration
(FDA) is announcing the following
public meeting: ‘‘Advancing Regulatory
Science for Highly Multiplexed
Microbiology/Medical Countermeasure
Devices.’’ The purpose of the public
meeting is to discuss performance
evaluation of highly multiplexed
microbiology/medical countermeasure
(MCM) devices, their clinical
application and public health/clinical
needs, and quality criteria for
establishing the accuracy of reference
databases. These considerations are
essential to establish the safety and
effectiveness of highly multiplexed
devices when used for the clinical
diagnosis of infectious diseases from a
human specimen.
Date and Time: The public meeting
will be held on October 13, 2011, from
8 a.m. to 6 p.m.
Location: The public meeting will be
held at the FDA White Oak Campus,
10903 New Hampshire Ave., Bldg. 31,
E:\FR\FM\08AUN1.SGM
08AUN1
Agencies
[Federal Register Volume 76, Number 152 (Monday, August 8, 2011)]
[Notices]
[Pages 48168-48169]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-19976]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0126]
Andrew K. Choi: Debarment Order
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is issuing an order
under the Federal Food, Drug, and Cosmetic Act (the FD&C Act) debarring
Andrew K. Choi, M.D. for 4 years from providing services in any
capacity to a person that has an approved or pending drug product
application. FDA bases this order on findings that Dr. Choi was
convicted of a misdemeanor under Federal law for conduct relating to
the regulation of a drug product under the FD&C Act and that the type
of conduct underlying the conviction undermines the process for the
regulation of drugs. Dr. Choi was given notice of the proposed
debarment and an opportunity to request a hearing within the timeframe
prescribed by regulation. Dr. Choi failed to respond. Dr. Choi's
failure to respond constitutes a waiver of his right to a hearing
concerning this action.
DATES: This order is effective August 8, 2011.
ADDRESSES: Submit applications for termination of debarment to the
Division of Dockets Management (HFA-305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Kenny Shade, Division of Compliance
Policy (HFC-230), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-796-4640.
SUPPLEMENTARY INFORMATION:
[[Page 48169]]
I. Background
Section 306(b)(2)(B)(i)(I) of the FD&C Act (21 U.S.C.
335a(b)(2)(B)(i)(I)) permits FDA to debar an individual if it finds
that the individual has been convicted of a misdemeanor under Federal
law for conduct relating to the regulation of drug products under the
FD&C Act, and if FDA finds that the type of conduct that served as the
basis for the conviction undermines the process for the regulation of
drugs.
On April 2, 2007, Dr. Choi pleaded guilty to one count of receipt
in interstate commerce of a misbranded drug and delivery thereof in
violation of sections 301(c), 303(c), and 502(f) of the FD&C Act (21
U.S.C. 331(c), 333(a)(1), and 352(f)). On August 11, 2008, the U.S.
District Court for the Central District of California entered judgment
against Dr. Choi for the misdemeanor offense of receipt in interstate
commerce of a misbranded drug and delivery thereof.
FDA's finding that debarment is appropriate is based on the
misdemeanor conviction referenced herein. The factual basis for the
conviction is as follows: Dr. Choi was a licensed physician in the
State of California. Prior to November 13, 2003, Dr. Choi injected
patients with Botox[supreg], an FDA-approved Botulinum Toxin Type A
drug product manufactured by Allergan, Inc. In 2003, Dr. Choi began
ordering an unapproved drug purported to be Botulinum Toxin Type A
(TRI-Toxin) manufactured by Toxin Research International, Inc. (TRI),
located in Tucson, Arizona, instead of the approved Botox[supreg]. From
on or about November 13, 2003, and continuing until about August 3,
2004, Dr. Choi placed 14 orders for a total of 28 vials of TRI-Toxin,
which he had shipped to his office in the Central District of
California. The TRI-Toxin did not come with labeling or directions on
how to dilute the product for injection. The TRI-Toxin label stated
``for research purposes only'' and ``not for human use,'' as did the
TRI-Toxin invoices. Dr. Choi admitted to injecting the TRI-Toxin into
his employees and patients. Between on or about November 13, 2003, and
continuing until on or about August 3, 2004, Dr. Choi received and
delivered the TRI-Toxin when he administered it to other persons, all
in violation of sections 301(c), 303(c), and 502(f) of the FD&C Act.
As a result of his conviction, on April 22, 2011, FDA sent Dr. Choi
a notice by certified mail proposing to debar him for 4 years from
providing services in any capacity to a person that has an approved or
pending drug product application. FDA subsequently confirmed on May 9,
2011, that Dr. Choi personally received the notice. The proposal was
based on a finding, under section 306(b)(2)(B)(i)(I) of the FD&C Act
that Dr. Choi was convicted of a misdemeanor under Federal law for
conduct relating to the regulation of drug products under the FD&C Act,
and that the conduct that served as a basis for the conviction
undermines the process for the regulation of drugs. The proposal also
offered Dr. Choi an opportunity to request a hearing, providing him 30
days from the date of receipt of the letter in which to file the
request, and advised him that failure to request a hearing constituted
a waiver of the opportunity for a hearing and of any contentions
concerning this action. Dr. Choi failed to respond within the timeframe
prescribed by regulation and has therefore, waived his opportunity for
a hearing and waived any contentions concerning his debarment (21 CFR
part 12).
II. Findings and Order
Therefore, the Director, Office of Enforcement, Office of
Regulatory Affairs, under section 306(b)(2)(B)(i)(I) of the FD&C Act
under authority delegated to him (Staff Manual Guide 1410.35), finds
that Andrew K. Choi has been convicted of a misdemeanor under Federal
law for conduct relating to the regulation of a drug product under the
FD&C Act, and that the type of conduct that served as a basis for the
conviction undermines the process for the regulation of drugs.
As a result of the foregoing finding, Dr. Choi is debarred for 4
years from providing services in any capacity to a person with an
approved or pending drug product application under sections 505, 512,
or 802 of the FD&C Act (21 U.S.C. 355, 360b, or 382), or under section
351 of the Public Health Service Act (42 U.S.C. 262), effective (see
DATES), (see sections 306(c)(1)(B), (c)(2)(A)(iii), and 201(dd) of the
FD&C Act (21 U.S.C. 335a(c)(1)(B), (c)(2)(A)(iii), and 321(dd))). Any
person with an approved or pending drug product application who
knowingly employs or retains as a consultant or contractor, or
otherwise uses the services of Dr. Choi, in any capacity during Dr.
Choi's debarment, will be subject to civil money penalties (section
307(a)(6) of the FD&C Act (21 U.S.C. 335b(a)(6))). If Dr. Choi provides
services in any capacity to a person with an approved or pending drug
product application during his period of debarment he will be subject
to civil money penalties (section 307(a)(7) of the FD&C Act). In
addition, FDA will not accept or review any abbreviated new drug
applications submitted by or with the assistance of Dr. Choi during his
period of debarment (section 306(c)(1)(B) of the FD&C Act).
Any application by Dr. Choi for termination of debarment under
section 306(d)(1) of the FD&C Act (21 U.S.C. 335a(d)(1)) should be
identified with Docket No. FDA-2011-N-0126 and sent to the Division of
Dockets Management (see ADDRESSES). All such submissions are to be
filed in four copies. The public availability of information in these
submissions is governed by 21 CFR 10.20(j).
Publicly available submissions may be seen in the Division of
Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.
Dated: July 27, 2011.
Armando Zamora,
Acting Director, Office of Enforcement, Office of Regulatory Affairs.
[FR Doc. 2011-19976 Filed 8-5-11; 8:45 am]
BILLING CODE 4160-01-P